A medication that functions similarly to Viagra by relaxing blood vessels and increasing blood flow to the brain has demonstrated the ability to slow cognitive decline in Alzheimer’s patients by nearly one-third, according to new global study results. The findings were presented at the Clinical Trials on Alzheimer’s Disease conference in Boston, offering a potential new avenue for treating a condition currently affecting millions, with projections indicating it will impact 153 million people globally by 2050.
The study, a stage three trial conducted across 13 countries including the UK, focused on the drug AR1001, a phosphodiesterase-5 inhibitor developed by the South Korean firm AriBio. The trial data showed that in 604 participants with early Alzheimer’s disease who were not receiving other treatments, the once-a-day tablet slowed cognitive decline by 31%. However, researchers noted that the results did not reach statistical significance among a broader group of patients who were concurrently taking other Alzheimer’s medications.
Experts in the field have reacted with cautious optimism. Prof Tara Spires-Jones, a professor of neurodegeneration at the University of Edinburgh and a fellow at the Academy of Medical Sciences, described the results as “very promising,” noting that the drug’s mechanism likely involves boosting blood flow and directly stimulating pathways within brain cells that support memory and learning. Dr Sheona Scales, director of research at Alzheimer’s Research UK, characterized the findings as an “important milestone,” highlighting that the drug’s approach—targeting a specific enzyme and influencing various brain function processes rather than focusing solely on amyloid—is particularly interesting.
Dr Richard Oakley, associate director of research and innovation at the Alzheimer’s Society, emphasized that the data suggests a potential for a novel treatment that addresses the causes of early Alzheimer’s rather than just the symptoms. He also noted that the drug’s delivery as a daily oral tablet could simplify treatment regimens, with participants reporting only mild to moderate side effects. Despite this, Oakley stressed that the drug’s reduced effectiveness in patients already taking other Alzheimer’s medications requires further investigation. He also clarified that while AR1001 is from the same family of medicines as Viagra, it is being developed specifically for Alzheimer’s, and people should not take Viagra to attempt to treat the disease.
All experts involved in the discussion underscored that these findings must undergo rigorous scrutiny by the scientific community and drug regulatory bodies before the medication can be approved for clinical use.
“Nonetheless, this is an encouraging development in Alzheimer’s research and reinforces the importance of exploring different approaches to tackling this complex disease.”





